Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: MK0869, aprepitant; Drug: Comparator: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00034944

0869-063

2006_403

Details and patient eligibility

About

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Full description

The duration of treatment is 8 weeks.

Enrollment: 495 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Major depressive disorder